Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye drops, designed to delay myopia progression in children aged 6-12, has been accepted by the National Medical Products Administration (NMPA). The product targets children with spherical diopters ranging from -0.50D to -4.00D and astigmatism/anisometropia ≤ 1.50D.
Product Profile
HR19034, developed using B/F/S three-in-one filling technology, contains atropine sulfate as the active ingredient. The preservative-free eye drops work by antagonizing muscarinic acetylcholine M receptors, regulating retinal and scleral function, improving choroidal blood supply, and inhibiting axial elongation to slow myopia progression.
Market Context
Similar products on the market include atropine sulfate eye drops from Aspen Group (Australia), Entod Pharmaceuticals (India), Santen Pharmaceutical (Japan), and Shenyang Xingqi Pharmaceutical (China).-Fineline Info & Tech
Leave a Reply